293 results about "Hepatovirus" patented technology

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

The invention relates to an enantiomorphic amine alkyl sesquiterpene alcohol and glucoside and the medicated salt or solvent thereof, as well as the effect and activity of the composed medicine combination, mainly relating to the medical use in reducing HBV-DNA replication activity. And it has considerably strong inhibiting effect on HBsAG screted by HepG2.2.15 and HBV-DNA replication as compared with positive contrast Lamivudine; and it has obvious inhibition activity to HBV-DNA replication at large dosage (100 mug / mL) and medium dosage(20 mug / mL) as contrasted with Lamivudine, and can be expected to apply to preparing medicines for curing HB virus infection disease.

The invention involves A 1- beta-keto-5, 11(13)-diene eudesmane-12-acidum who has the structure as formula (1) shows and its medical salt, or solvate and its drug combinations and its medical usage in reducing hepatitis B surface antgien and inhibiting replication activity of aethyl- hepatovirus HBV-DNA medicinal. The invention compounds has strong inhibitory action in hepatitis B surface antgien (HBsAg) externalized by HepG2.2.15 cells and replication of aethyl- hepatovirus deoxyribonucleotide (HBV-DNA) in vitro, its inhibiting ability against HBsAg surpasses that of positive control Lamivudine in the same dose; it has obvious inhibiting ability against replication of aethyl- hepatovirus HBV-DNA under the concentration of 100 mu g / mL,20 mug / mL and 4 mug / mL DNA, it belongs to anti- aethyl- hepatovirus natural products of superactive non-nucleoside, can be expected for producing drugs for treating aethyl- hepatovirus infected disease.

The invention relates to a hemiterpene derivant 2-Hydroxyilicic acid, as formula (1) 2beta-hydroxy-5alphaH-eudesmane-11(13)-allyl-12-acid and relative compounds which can be used to prepare the drug treating hepatitis B disease. The inventive compound can restrain the copy of hepatitis B surface antigen (HBsAg) and the hepatitis B deoxyribonucleic acid (HBV-DNA), while its HBsAg restrain ability is higher than positive contrast difuradin; in the density as 100mug / ml, 20mug / ml, and 4mug / ml, it can restrain the copy of hepatitis B virus HBV-DNA.

The present invention relates to an eudesmane type sesquiterpene derivative 1 beta-hydroxyilicic acid, namely 1 beta-hydroxy-5 alpha H-eudesmane-11 (13)-ethylene-12-acid, its medicineal salt or solvent compound and its medicine composition and medicinal application for preparing medicine capable of curing hepatitis B virus infective disease and resisting hepatitis B virus. Said invention also provides its chemical structure formula.

The invention relates to the medicine technical field and concretely relates to a mixture formed by two enantiomorphous eremophilane acids separated from murrey ligularia and the officinal salt as well as the medicine combined material. The enantiomorphous eremophilane acid can be used for preparing the medicine curing hepatitis B virus infectious diseases due to the ability of suppressing the antigenic activity on the surface of hepatitis B virus.

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

The present invention provides for the treatment or prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae infection. In particular, the invention provides compositions and methods that affect the ability of Hepadnaviridae to utilize the host's cellular machinery as part of the virus' lifecycle. The invention relates to the discovery that interfering with the normal ability of viruses to utilize the host cell machinery with LSD1 inhibitors reduces HBV replication. Thus, the treatment and prevention of Hepadnaviridae infection and disease caused by Hepadnaviridae according to the invention comprises administering to an individual in need of treatment, a therapeutically effective amount of a LSD1 inhibitor. The individual in need of treatment can be a human or, e.g., another mammal.

The invention relates to a silibinin monoester derivative and its medicine salt or solvates. The invention also relates to its preparation method and its drug combination and medical application. The compound can inhibit activity of hepatitis b virus, so it is expected to be used as drug to treat hepatitis b virus and relevant virus diseases. The compound can protect liver and is expected to be used as drug preventing liver damage. The compound possesses effect anti free radical and is expected to be used as drug treating diseases caused by free radical.

The invention relates to application of diallyl propyl flavonolignan in preparation a medicament for curing hepatitis B, in particular to application of a flavonolignan or pharmaceutically acceptable salts thereof in preparation of the medicament for curing the hepatitis B by clearing hepatitis B e-antigen and inhibiting HBV DNA replication. The flavonolignan has hepatitis B virus e-antigen (HBeAg) inhibiting activities, and has the inhibition strength higher than a positive control first-line medicament, namely lamivudine and alpha-interferon, at a low concentration of 20 mu g / ml; simultaneously, at the concentration of 5 mu g / ml, the compound has an inhibition rate of the HBV DNA of over 70 percent; and therefore, the flavonolignan can be expected for preparing the medicament for curing the hepatitis B virus infection diseases by clearing the hepatitis B e-antigen and inhibiting the HBV DNA replication.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

The invention discloses a graphene modified natural emulsion preparation method and a high barrier condom. The graphene modified natural emulsion preparation method and the high barrier condom have the beneficial effects that firstly graphene and a dispersing agent mixed liquor are mixed, ground and stirred and then the product is mixed in a natural emulsion aqueous solution, so that graphene can be uniformly dispersed in emulsion and the strength of a natural emulsion composite material is improved; meanwhile, the number of micropores is smaller due to the graphene / emulsion composite action, thus greatly reducing the virus penetration probability; the thickness of the graphene condom can be 5-80mu m, so that the use requirements of the condom can be met; dense high barrier packing layers are formed by the composite crosslinked nano-packing technology, so that the natural gaps among molecules are reduced; therefore not only can HIVs be blocked but also hepatitis B viruses, hepatitis C viruses, human papilloma viruses, and the like, and most harmful bacteria, which are smaller than the HIVs, can not pass through the micropores.

The invention provides a phenanthridine compound with an effect of resisting hepatitis B and hepatitis C, a medicinal composition taking the same as an active medicine component, a preparation method and applications of the phenanthridine compound in preparing a medicine for resisting hepatitis C viruses, and preparing an anti-virus medicine. According to the invention, the activity of benzylphenethylamine alkaloid in resisting various viruses is discovered in a process of studying a plant anti-virus natural product, and an obvious effect in resisting viruses of hepatitis B and hepatitis C of a phenanthridine derivative is discovered through structure modification, structure-function relationship and structure optimization.

The present invention relates to therapeutic protocols and pharmaceutical compositions designed to target HBx mediated activation of Src kinase, members of the Src tyrosine kinase family and components of the Src kinase family signal transduction pathways for the treatment of HBV infection and related disorders and diseases, such as HCC. The invention further relates to pharmaceutical compositions for the treatment of HBV infection targeted to HBx and its essential activities required to sustain HBV replication. The invention is based, in part, on the Applicants' discovery that activation of Src kinase signaling cascades play a fundamental role in mammalian hepadnavirus replication. Applicants have demonstrated that HBx mediates activation of the Src family of kinases and that this activation is a critical function provided by HBx for mammalian hepadnavirus replication.

The invention discloses the medical application of a 15-methylene replaced andrographolide derivant as shown in general formula 1, more particularly relates to the application thereof in preparing anti-hepatitis B virus drugs, pertaining to the pharmaceutical chemistry field. HepG2.2.15 cells are used for detecting the secretory volumes of HBsAg and HBeAg and the HBV DNA level related to viral particles in the supernatant liquid of a nutrient solution, and the result shows that the 15-methylene replaced andrographolide derivant has good in-vitro anti-HBV effect. The 15-methylene replaced andrographolide derivant has better development and application prospect by being applied in preparing drugs used for treating and preventing Hepatitis B.

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and / or preventing diseases relevant to HCV infection.

The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

The invention belongs to the field of gene therapy of diseases, relating to application of hepatitis B virus x protein gene (HBx) in preparing medicines for treating liver cancer and complicating diseases coupled with the liver cancer. The invention has the technical proposal to provide the application of the hepatitis B virus x protein gene (HBx) and encoded protein thereof in preparing the medicines for treating liver cancer and complicating diseases coupled with the liver cancer. In the invention, the hepatitis B virus x protein gene is recombined into an adenoviral vector to be used in medicines for treating the liver cancer; furthermore, activating transcription factors which are generally considered as virus promoters in the field are creatively engaged in virus pathogenic HBx protein for preparing medicines for treating the liver cancer and are proved to have good effect by in vitro and in vivo experiments, thus being well capable of treating the liver cancer and liver ascites,a complicating disease thereof and providing a new selection for liver cancer treatment in the field.

The invention relates to the technical field of medicaments and discloses the novel application of a penthorum chinense pursh extract or compounds of ursolic acid, pinocembrin, scopoletin, gallic acid, ursolic acid-28-xylose-(1-3)-glucoside, pinocembrin-7-glucoside, pinocembrin-7-neohesperidoside, scopolin or galloyl glucoside separated from the penthorum chinense pursh extract. Pharmacological and pharmacodynamic tests show that the penthorum chinense pursh extract or the compounds can obviously reduce the rising of aspartate aminotransferase (AST), glutamic-pyruvic transaminase (ALT) and alkaline phosphatase (ALP), caused by acute liver injury, alcoholic liver and virus hepatitis in mice, chronic hepatic fibrosis in rats and the like, has an obvious inhabitation effect on HepG2 tumor cells and can reduce the cholesterol and triglycercide content of blood serum. The penthorum chinense pursh extract or the compounds are simple in preparation method and low in cost. The invention provides a new medicament source for preventing and treating hepatitides, liver injury, hepatic fibrosis, cirrhosis, alcoholic liver, liver cancer and diseases associated with high blood fat.

The invention belongs to the field of hepatitis B virus infected cell models in life sciences and medicine, and provides a liver precursor-like cell model derived from a primary hepatocyte for hepatitis B virus infection, a preparation method and application. The liver precursor-like cell model consists of functional liver cells after three-dimensional differentiation, and the functional liver cells after three-dimensional differentiation are obtained by liver precursor-like cells obtained after in vitro conversion and cultivation of human primary hepatocytes after three-dimensional cultivation and liver maturation cultivation. Through experimental verification, after the liver precursor-like cell model is infected with HBV, the related genes of HBV infections such as RXRA, HNF4A, NTCP andthe like can be expressed highly, and the cell model can be used in hepatitis B virus infection research or can be co-cultured with HBV for preparing a hepatitis B virus infection cell model.

The present invention provides a composition comprising hepatitis B virus (HBV) component(s), and which may be either nucleic acid- or polypeptide-based as well as nucleic acid molecules and vectors encoding such HBV component(s). It also relates to infectious viral particles and host cells comprising such nucleic acid molecules or vectors. It also provides composition and kits of parts comprising such nucleic acid molecules, vectors, infectious viral particles or host cells and the therapeutic use thereof for preventing or treating HBV infections.

The invention discloses a multiple PCR (Polymerase Chain Reaction) detection kit for duck hepatitis A virus 1 and 3 as well as MDPV (Muscovy Duck Parvovirus). The detection kit contains three pairs of specific primers. Experimental results show the multiple PCR detection kit for duck hepatitis A virus 1 and 3 as well as MDPV can be applied to detecting the duck hepatitis A virus 1 and 3 and the MDPV. The multiple PCR detection kit has the advantages of being convenient to operate, high in sensitivity, strong in specificity and the like; furthermore, the multiple PCR detection kit can be clinically used for distinguishing and detecting the duck hepatitis A virus 1 and 3 and the MDPV, the time cost can be saved, and the pollution can be reduced.

The invention belongs to the technical field of molecular biology and particularly relates to NDV (Newcastle disease virus) recombinant virus expressing DHAV-1 and DHAV-3 VP1 genes.The recombinant virus is recorded as rLS-1VP1-2A-3VP1 and is obtained inserting serially connected DHAV-1 and DHAV-3 VP1 genes into an NDV vector and carrying out saving.The NDV (Lasota strain) is used as the vector for the recombinant virus, the serially connected DHAV-1 and DHAV-3 VP1 genes are inserted into the NDV (Lasota strain) to obtain a vector, and the DNV recombinant virus co-expressing DHAV-1 and DHAV-3 VP1 genes is obtained by determining an optimal insertion site to insert the DHAV VIP1 gene; the recombinant virus is useful in preventing duck hepatitis A viruses (type 1 and type 3) and duck Newcastle disease and filling the current blank of DHAV-3 vaccines.

The invention discloses a kit and method for detecting duck hepatitis A viruses through dual TaqMan fluorescent quantitation RT-PCR. Primer pairs and probes applied to the kit comprise primer pairs and probes for detecting type-1 duck hepatitis A virus VP0 genes and type-3 duck hepatitis A virus VP3 genes. After sample RNA is subjected to RT-PCR amplification, the result is automatically analyzed and read through software of an FQ-PCR instrument, and whether the sample contains type-1 duck hepatitis A viruses and type-3 duck hepatitis A viruses or not is judged; if logarithmically-growing specific amplification curves in which Ct<35 exist, it is shown that the sample contains the type-1 duck hepatitis A viruses and / or the type-3 duck hepatitis A viruses; if no logarithmically-growing specific amplification curve in which Ct<35 exists, the sample does not contain the type-1 duck hepatitis A viruses and / or the type-3 duck hepatitis A viruses. The kit and method are adopted for detecting the type-1 duck hepatitis A viruses and the type-3 duck hepatitis A viruses, the two kinds of viruses can be synchronously detected in the same tube, detection time is short, cost is low, the detection result is specific, sensitivity is high, and result judgment is simple and accurate.

The invention discloses a general type duck hepatitis A virus antibody ELISA (Enzyme-Linked Immunosorbent Assay) detection kit which comprises an ELISA plate coated with DHAV (Duck Hepatitis A Virus)-1VP3-3VP1 recombinant protein. The DHAV-1VP3-3VP1 recombinant protein is obtained through a method which comprises the following steps: respectively amplifying and cloning a DHAV-1VP3 gene and a DHAV-1VP1 gene by taking DHAV-1 and DHAV-3 as materials to obtain recombinant plasmids pMD-1VP3 and pMD-3VP1; then directionally inserting into a pET-32a(+) expression vector in series, and screening to obtain a recombinant expression plasmid pET-1VP3-3VP1; and carrying out ITPG (Isopropyl beta-D-thiogalactoside) inducible expression and purification to obtain the DHAV-1VP3-3VP1 recombinant protein. The general type duck hepatitis A virus antibody ELISA detection kit disclosed by the invention can be used for evaluating the levels of DHAV-1 and DHAV-3 antibodies through primary detection and is low in cost, easy, convenient and fast to operate and suitable for the detection of batch samples.

The invention discloses a primer, a probe and a kit used for predicting liver cancer caused by hepatitis B virus (HBV). The primer and the probe are designed according to mutation sites of HBV. The mutation sites comprise the following 14: C1653T, T1674C, T1753V, A1762T, G1764A, A1846T, A1858T, G1896A, G1899A, C1485T, C1499H, G1613A, C3116T and T53C. According to the invention, early stage prediction of hepatocellular carcinoma is realized through detections upon the 14 mutation sites of HBV. Also, the invention provides a method for detecting HBV mutation sites.

The invention discloses a reagent kit for identifying duck hepatitis A virus infection and novel duck reovirus infection. Specific primers (such as SEQ No. (sequence number) 1-4) of a duck hepatitis A virus and a novel duck reovirus are adopted to establish a double PCR (Polymerase Chain Reaction) detection method, and assembled into the reagent kit. The reagent kit can identify the duck hepatitis A virus and the novel duck reovirus in the same system and the mixed infection of the duck hepatitis A virus and the novel duck reovirus. The reagent kit has the characteristics of quickness, accuracy, high sensitivity, good specificity and the like, and can well solve the problem that the duck hepatitis A virus infection and the novel duck reovirus infection are difficult to distinguish clinically.